1264239-56-6

Usage

Uses

Used in Pharmaceutical Applications:
(S)-5-allyl 1-benzyl 2-(methylamino)pentanedioate hydrochloride is used as an active pharmaceutical ingredient for [application reason]. Its unique structure and functionality contribute to its potential as a candidate for drug development and medicinal chemistry studies.
Used in Organic Synthesis:
(S)-5-allyl 1-benzyl 2-(methylamino)pentanedioate hydrochloride is used as a reagent or intermediate in organic synthesis for [application reason]. Its versatile molecular structure allows for various chemical reactions and modifications, making it a valuable compound in the synthesis of other complex molecules.
Used in Research Purposes:
(S)-5-allyl 1-benzyl 2-(methylamino)pentanedioate hydrochloride is used as a research tool for [application reason]. Its unique properties and potential applications make it an interesting subject for further investigation and study in the fields of chemistry and biology.

Upstream product

• 1264239-47-5 C₂₁H₂₂N₂O₈S 
• 132245-80-8 C₂₀H₂₇NO₆ 
• 1264239-51-1 C₂₂H₂₄N₂O₈S 
• 1264239-42-0 C₁₅H₁₉NO₄*ClH 
• 132286-79-4 N-α-(t-butoxycarbonyl)-L-glutamic γ-allyl ester 
• 100-39-0 benzyl bromide 

Downstream Products

• 1264221-48-8 8-benzyl 2-[2-(trimethylsilyl)ethyl] (2S,8S,16aS)-12-fluoro-8-methyl-5,10-dioxo-2,3,5,6,7,8,9,10,16,16a-decahydro-1H-pyrrolo-[2,1-c][1,4,9]benzoxadiazacyclododecine-2,8-dicarboxylate 
• 1264221-58-0 benzyl (2S,11S,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate 
• 1264241-31-7 C₄₀H₅₁FN₄O₁₁ 
• 1264241-36-2 C₃₃H₄₃FN₄O₉ 
• 1264243-67-5 benzyl (2S,11S,19aS)-2-amino-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate 
• 1264243-21-1 C₄₀H₅₂N₄O₁₀S 
• 1264241-70-4 C₃₇H₄₆FN₃O₁₀ 
• 1264240-00-7 (S)-5-allyl 1-benzyl 2-(5-fluoro-2-hydroxy-N-methylbenzamido)pentanedioate 
• 1264240-92-7 (S)-5-allyl 1-benzyl 2-(3-mercapto-N-methylbenzamido)pentanedioate 
• 1264241-21-5 C₃₈H₅₀FN₃O₁₀Si 
• 1264241-26-0 C₃₁H₄₂FN₃O₈Si 
• 1264240-87-0 C₂₅H₂₇NO₆S 
• 1264224-46-5 benzyl (2S,11S,19aS)-2-(acetylamino)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate 
• 1264221-69-3 benzyl (2S,11S,19aS)-2-amino-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate hydrochloride 

Relevant academic research and scientific papers

CONFORMATION-LOCKED, SYNTHETIC MACROCYCLIC COMPOUND

PROBLEM TO BE SOLVED: To provide a compound effective for treating: diabetic gastroparesis, and impairment of hypomotility in the gastrointestinal tract such as constipation type irritable bowel syndrome; CNS related disorders such as migraine, schizophre

Conformation-constrained entirely-synthetic macrocyclic compounds

The invention relates to conformation-constrained entirely-synthetic macrocyclic compounds. A conformation-constrained, space-defined 12-30-member macrocyclic system (I) which is as shown in the description comprises three different constitution units: an aromatic template a, a confor1ation regulator b and a spaced part c, which are illustrated in the description and the claims. The macrocyclic compounds (I) can be easily prepared according to a parallel synthesis method or a combinatorial chemistry method, and are designed for realizing interaction with a specific biological target. Particularly, the compounds show agonistic or antagonistic activity to the following matters: a motilin receptor (MR), a 5-hydroxytryptamine receptor (5-HT2B receptor) of a subtype 5-HT2B, and a prostaglandin F2alpha receptor (FP receptor). Thus, the compounds are effectively used for treating gastrointestinal tract hypomotility disorder such as diabetic gastroparesis and constipation-predominant irritable bowel syndrome, CNS-related diseases such as migraine, schizophrenia, psychosis and depression, ocular hypertension such as glaucoma-related ocular hypertension, and premature delivery.

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT2B (5-HT2B receptor), and on the prostaglandin F2?receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y1, as modulators of the serotonin receptor of subtype 5-HT2B, as blockers of the voltage-gated potassium channel Kv1.3 and as inhibitors of the β-catenin-dependent “canonical” Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT2B (5-HT2B receptor), and on the prostaglandin F2 ? receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.